SKIN vs USNA

For growth investors, USANA Health Sciences, Inc.

(USNA) is the stronger pick with 8. 3% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). USANA Health Sciences, Inc. (USNA) offers the better valuation at 34. 5x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate The Beauty Health Company (SKIN) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, USANA Health Sciences, Inc.

(USNA) delivered a total return of -79. 7%, compared to -92. 7% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: USNA returned -68. 7% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), USANA Health Sciences, Inc.

(USNA) is the lower-risk stock at 1. 34β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 48% more volatile than USNA relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), USANA Health Sciences, Inc.

(USNA) is pulling ahead at 8. 3% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -73. 5% for USANA Health Sciences, Inc.. Over a 3-year CAGR, USNA leads at -2. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

USANA Health Sciences, Inc.

(USNA) is the more profitable company, earning 1. 2% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USNA leads at 5. 5% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — USNA leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for USNA: 74.

9% to $35. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, USANA Health Sciences, Inc.

(USNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (USNA: -68. 7%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.